Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $5.44 and last traded at $5.39, with a volume of 4441530 shares traded. The stock had previously closed at $4.99.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen cut Prime Medicine from a "hold" rating to a "sell" rating in a research report on Tuesday, September 2nd.
Get Our Latest Stock Report on PRME
Prime Medicine Stock Up 8.0%
The company has a market capitalization of $725.35 million, a P/E ratio of -3.46 and a beta of 2.39.
About Prime Medicine
(
Get Free Report)
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prime Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.
While Prime Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
